UA110604C2 - Кристалічна форма поліциклічної сполуки - Google Patents
Кристалічна форма поліциклічної сполуки Download PDFInfo
- Publication number
- UA110604C2 UA110604C2 UAA201203501A UAA201203501A UA110604C2 UA 110604 C2 UA110604 C2 UA 110604C2 UA A201203501 A UAA201203501 A UA A201203501A UA A201203501 A UAA201203501 A UA A201203501A UA 110604 C2 UA110604 C2 UA 110604C2
- Authority
- UA
- Ukraine
- Prior art keywords
- shk
- shi
- compound
- still
- shchi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23718009P | 2009-08-26 | 2009-08-26 | |
| PCT/US2010/046671 WO2011028580A1 (en) | 2009-08-26 | 2010-08-25 | Novel forms of a multicyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA110604C2 true UA110604C2 (uk) | 2016-01-25 |
Family
ID=43033463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201203501A UA110604C2 (uk) | 2009-08-26 | 2010-08-25 | Кристалічна форма поліциклічної сполуки |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8633314B2 (enExample) |
| EP (1) | EP2470540B1 (enExample) |
| JP (3) | JP2013503173A (enExample) |
| KR (1) | KR20120092100A (enExample) |
| CN (1) | CN102482282A (enExample) |
| AU (1) | AU2010289746B2 (enExample) |
| BR (1) | BR112012004053A2 (enExample) |
| CA (1) | CA2772328C (enExample) |
| CL (1) | CL2012000478A1 (enExample) |
| DK (1) | DK2470540T3 (enExample) |
| EA (1) | EA020756B1 (enExample) |
| ES (1) | ES2572652T3 (enExample) |
| IL (1) | IL218132B (enExample) |
| MX (1) | MX2012002456A (enExample) |
| MY (1) | MY156873A (enExample) |
| NZ (1) | NZ598883A (enExample) |
| SG (1) | SG178852A1 (enExample) |
| UA (1) | UA110604C2 (enExample) |
| WO (1) | WO2011028580A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503173A (ja) * | 2009-08-26 | 2013-01-31 | セファロン、インク. | 多環系化合物の新規形態 |
| CA2967828A1 (en) | 2014-11-26 | 2016-06-02 | Cephalon, Inc. | Crystalline forms of parp inhibitors |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| US20060276497A1 (en) | 2000-05-09 | 2006-12-07 | Cephalon, Inc. | Novel multicyclic compounds and the use thereof |
| CN101316592A (zh) * | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| WO2008063644A1 (en) | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| JP2013503173A (ja) * | 2009-08-26 | 2013-01-31 | セファロン、インク. | 多環系化合物の新規形態 |
-
2010
- 2010-08-25 JP JP2012526945A patent/JP2013503173A/ja active Pending
- 2010-08-25 CA CA2772328A patent/CA2772328C/en not_active Expired - Fee Related
- 2010-08-25 DK DK10750210.6T patent/DK2470540T3/en active
- 2010-08-25 EP EP10750210.6A patent/EP2470540B1/en active Active
- 2010-08-25 MY MYPI2012000710A patent/MY156873A/en unknown
- 2010-08-25 NZ NZ598883A patent/NZ598883A/en not_active IP Right Cessation
- 2010-08-25 WO PCT/US2010/046671 patent/WO2011028580A1/en not_active Ceased
- 2010-08-25 KR KR1020127007524A patent/KR20120092100A/ko not_active Ceased
- 2010-08-25 EA EA201270315A patent/EA020756B1/ru not_active IP Right Cessation
- 2010-08-25 CN CN2010800380284A patent/CN102482282A/zh active Pending
- 2010-08-25 SG SG2012012290A patent/SG178852A1/en unknown
- 2010-08-25 UA UAA201203501A patent/UA110604C2/uk unknown
- 2010-08-25 BR BR112012004053-7A patent/BR112012004053A2/pt not_active IP Right Cessation
- 2010-08-25 ES ES10750210.6T patent/ES2572652T3/es active Active
- 2010-08-25 AU AU2010289746A patent/AU2010289746B2/en not_active Ceased
- 2010-08-25 MX MX2012002456A patent/MX2012002456A/es active IP Right Grant
-
2012
- 2012-02-15 IL IL218132A patent/IL218132B/en not_active IP Right Cessation
- 2012-02-24 US US13/404,137 patent/US8633314B2/en not_active Expired - Fee Related
- 2012-02-24 CL CL2012000478A patent/CL2012000478A1/es unknown
-
2015
- 2015-07-30 JP JP2015151114A patent/JP2016014029A/ja not_active Ceased
-
2017
- 2017-09-04 JP JP2017169876A patent/JP2018035158A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CL2012000478A1 (es) | 2012-11-05 |
| EP2470540A1 (en) | 2012-07-04 |
| JP2018035158A (ja) | 2018-03-08 |
| MX2012002456A (es) | 2012-05-08 |
| CA2772328A1 (en) | 2011-03-10 |
| EA020756B1 (ru) | 2015-01-30 |
| EA201270315A1 (ru) | 2012-08-30 |
| AU2010289746B2 (en) | 2016-07-07 |
| JP2016014029A (ja) | 2016-01-28 |
| WO2011028580A1 (en) | 2011-03-10 |
| MY156873A (en) | 2016-04-15 |
| KR20120092100A (ko) | 2012-08-20 |
| NZ598883A (en) | 2014-09-26 |
| BR112012004053A2 (pt) | 2020-12-08 |
| EP2470540B1 (en) | 2016-04-20 |
| AU2010289746A1 (en) | 2012-04-12 |
| CA2772328C (en) | 2017-06-20 |
| ES2572652T3 (es) | 2016-06-01 |
| HK1171750A1 (zh) | 2013-04-05 |
| CN102482282A (zh) | 2012-05-30 |
| US8633314B2 (en) | 2014-01-21 |
| JP2013503173A (ja) | 2013-01-31 |
| SG178852A1 (en) | 2012-04-27 |
| DK2470540T3 (en) | 2016-08-01 |
| US20120214998A1 (en) | 2012-08-23 |
| IL218132A0 (en) | 2012-06-28 |
| IL218132B (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI915407B (zh) | Apol1抑制劑及其使用方法 | |
| US20230040262A1 (en) | Stereoselective process for preparing substituted polycyclic pyridone derivatives | |
| CA2871464C (en) | Sulfonamide derivatives and their use in the inhibition of .alpha.4.beta.7 integrin-dependent process | |
| ES2639052T3 (es) | Forma polimórfica de hidrocloruro de pridopidina | |
| EP3315499B1 (en) | Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide | |
| CA2990521C (en) | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | |
| US8921363B2 (en) | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | |
| ES2450568T3 (es) | Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico | |
| AU2019309706A1 (en) | Elagolix sodium compositions and processes | |
| BR112017019779B1 (pt) | Composto, e, composição farmacêutica | |
| TW200306176A (en) | Chemical compounds | |
| JP2018035158A (ja) | 多環系化合物の新規形態 | |
| US20140031340A1 (en) | 5-Amino-Oxazepine and 5-Amino-Thiazepane Compounds as Beta Secretase Antagonists and Methods of Use | |
| CN104316608A (zh) | 阿齐沙坦酯杂质的检测及其制备方法 | |
| CN116375707A (zh) | Menin抑制剂及其用途 | |
| CN120774891A (zh) | 用于抑制Nav1.8的钠通道调节剂 | |
| MX2014007009A (es) | Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina. | |
| ES2784826T3 (es) | Forma cristalina de un compuesto de 4H-pirazol[1,5-]benzimidazol, procedimiento de preparación de la misma e intermediario de la misma | |
| ES2616752T3 (es) | Composición y cocristal de aprepitant L-prolina | |
| ES2926469T3 (es) | Cristales de un derivado de benzoxazol | |
| EA029975B1 (ru) | ТВЕРДЫЕ ФОРМЫ (1r,4r)-6'-ФТОР-(N,N-ДИМЕТИЛ)-4-ФЕНИЛ-4'9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИНА И СЕРНОЙ КИСЛОТЫ | |
| WO2014118180A1 (en) | Crystalline form of linaclotide | |
| RU2423992C1 (ru) | Способ получения пакистанамина и берберина хлорида из berberis sibirica | |
| KR102871840B1 (ko) | 거대고리 화합물 | |
| CN118165008A (zh) | 二苯并-1,3-氧氮杂环戊烷并异喹啉-1(2h)-酮类化合物及其制备方法和抗肿瘤应用 |